CFDE Data Portal | Search ZBTB41

	Label	Description
	ZBTB41 associations Collection (Entity type)	Associations for ZBTB41_associations
	GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE145990 1 V 0 IBRUTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE148200 0 V 2 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE168401 2 V 0 HARMINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE139987 1 V 2 ROSIGLITAZONE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE163862 2 V 3 CISPLATIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS

ZBTB41 associations

Associations for ZBTB41_associations

GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN

A Gene Set from LINCS

GSE145990 1 V 0 IBRUTINIB HUMAN UP

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn

A Gene Set from LINCS

GSE148200 0 V 2 GEMCITABINE HUMAN UP

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE168401 2 V 0 HARMINE HUMAN DN

A Gene Set from LINCS

GSE139987 1 V 2 ROSIGLITAZONE MOUSE DN

A Gene Set from LINCS

GSE163862 2 V 3 CISPLATIN MOUSE DN

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 8 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.